Without product revenue, Biophytis's principal risk is keeping access to financing while its value creation is driven principally by advancing its clinical development programmes and intellectual property portfolio instead of commercialising products.
The board describes a challenging environment for biotechnology companies, with selective access to capital markets, and competition for funding clinical development programmes is intense. Operating expenses consist primarily of research and development costs, intellectual property expenses, clinical trial costs, scientific and regulatory consulting fees, and the general and administrative expenses required to support the company’s operations.
Biophytis's economics today are a cost structure rather than a revenue engine: it generated no revenue during the financial year 2025, and its spending is concentrated in development rather than commercialisation. Its value creation strategy is driven principally by the advancement of its development programmes and its intellectual property portfolio rather than by the commercialisation of products.
Operating expenses consist primarily of research and development costs, intellectual property expenses, clinical trial costs, scientific and regulatory consulting fees, and the general and administrative expenses required to support the company's operations.
BIO101 is Biophytis's orally administered small molecule drug candidate, under development for neuromuscular and respiratory indications including sarcopenia, Duchenne muscular dystrophy, and respiratory failure, and it is aimed at preserving muscle function.
For obesity, BIO101 is being developed as a combination treatment with GLP-1 receptor agonists to counter muscle mass loss during weight loss management.